Montelukast prevents post-RSV-bronchiolitis wheeze
H. Bisgaard, M. Hermansen, C. Vrang, E. Andersen, G. Dybmose, V. Braendholt, K. Nielsen, E. Fog, L. Pedersen, B. Schmidt, B. Klug, J. Henriksen, M. Jorgensen, K. Bonnelykke (Copenhagen, Denmark)
Source: Annual Congress 2002 - Bronchiolitis
Session: Bronchiolitis
Session type: Oral Presentation
Number: 237
Disease area: Paediatric lung diseases
Abstract Infants often develop recurrent wheeze after respiratory syncytial virus (RSV) bronchiolitis. Cysteinyl-leukotrienes (cys-LT) are released during RSV infection and may cause many of the features of the resulting inflammation. We therefore hypothesized that a cys-LT receptor antagonist would ameliorate the recurrent wheeze subsequent to RSV bronchiolitis. Infants of 3-36 months, hospitalized with acute RSV bronchiolitis were randomized into a double-blind, parallel comparison of 5 mg montelukast chewable tablets or matching placebo given for 28 days starting up to 7 days after symptom debut. Symptoms were recorded on diary cards during the treatment period. Children with a suspected history of asthma were excluded. One hundred and thirty infants were randomized, and 116 provided diary card data; median age was 9 months. Children on montelukast were free of any symptoms on 22% of the days and nights compared to 4% of the days and nights in children on placebo (p=0.015). Day-time cough was significantly reduced on active treatment (p=0.04). All other symptom domains were consistently in favor of montelukast but did not reach statistical significance. Exacerbation rate (rescue steroid treatment, or emergency department visit or hospitalization for lung symptoms) was significantly reduced from montelukast compared with placebo (time to exacerbation 8 days on placebo and 23 days on montelukast, p<0.05). Conclusion: Cys-LT antagonist treatment reduces lung symptoms subsequent to RSV bronchiolitis.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Bisgaard, M. Hermansen, C. Vrang, E. Andersen, G. Dybmose, V. Braendholt, K. Nielsen, E. Fog, L. Pedersen, B. Schmidt, B. Klug, J. Henriksen, M. Jorgensen, K. Bonnelykke (Copenhagen, Denmark). Montelukast prevents post-RSV-bronchiolitis wheeze. Eur Respir J 2002; 20: Suppl. 38, 237
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Montelukast in exercise-induced asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 263s Year: 2006
Montelukast and frequency of exacerbations of asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Montelukast reduces viral-induced asthma exacerbations: the PREVIA study Source: Eur Respir J 2004; 24: Suppl. 48, 212s Year: 2004
Montelukast in cases of severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002
Not all who wheeze have asthma Source: Breathe 2010; 7: 16-22 Year: 2010
Montelukast for toddler asthma? A meta-analysis of montelukast in preschool wheeze Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016
The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children Source: Eur Respir J 2002; 20: 104-107 Year: 2002
Montelukast compared with fluticasone proprionate in children with persistent asthma Source: ISSN=ISSN 1810-6838, ISBN=, page=267 Year: 2006
Effect of fluticasone and montelukast in preschool children with asthma-like symptoms Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006
Effects of fluticasone propionate in young children with recurrent wheeze after RSV bronchiolitis Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome Year: 2007
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach Source: Eur Respir J 2008; 32: 1096-1110 Year: 2008
Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: 226-230 Year: 2004
Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Sustained reduction of bronchial hyperresponsiveness with inhaled fluticasone propionate in mild asthma within three days Source: Eur Respir J 2002; 20: Suppl. 38, 197s Year: 2002
Montelukast and budesonide therapy of asthmatic patients suffering from chronic cough Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
A persistent wheeze Source: Breathe, 17 (2) 210036; 10.1183/20734735.0036-2021 Year: 2021
Efficacy of single-dose Montelukast on exercise-induced bronchoconstriction in children Source: Eur Respir J 2001; 18: Suppl. 33, 495s Year: 2001
Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3 Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010